Post by sshl on Nov 8, 2017 16:10:42 GMT
this company just completed its IPO recently and has two drugs that are designed to treat obesity one in phase lll and the second just completed phase ll. "Our lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. Setmelanotide activates MC4R, which is part of a key pathway that can regulate energy homeostasis (i.e., the body’s energy balance) and appetite. The critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects in this pathway result in early-onset and severe obesity."
Has this been discussed on any thread before?
Has this been discussed on any thread before?
